RPS6KA1
Ribosomal protein S6 kinase alpha-1
As of the edition of 20 October 2026, RPS6KA1 (ribosomal protein S6 kinase alpha-1, UniProt Q15418) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15418
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 23
- Disease areas
- Cancer; Blood and lymph; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 3
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| PMD-026 | Active | Phase 2 | none listed |
| TAS0612 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Taiho | Route A |
The other 1 company at RPS6KA1
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at RPS6KA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.